A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Leena Gandhi, MD, PhD
NextPoint
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Albert Einstein Medical College Montefiore Medical Center
New York, New York, United States
- Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Next Oncology-San Antonio
San Antonio, Texas, United States
- Next Oncology-Fairfax
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Jul 2023
- Primary completion
- 20 Sept 2025
- Completion
- 20 Sept 2025
- Last update posted
- 27 Jun 2025
- Registered enrollment
- 131
- Registry id
- NCT05958199
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.